Galectin Therapeutics (NASDAQ:GALT) had its price objective cut by Roth Capital from $10.00 to $3.00 in a research report issued on Thursday. Roth Capital’s price objective would suggest a potential upside of 94.81% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective (up previously from $6.00) on shares of Galectin Therapeutics in a report on Thursday. ValuEngine downgraded Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, September 21st. Seaport Global Securities restated a “buy” rating and issued a $5.00 price target on shares of Galectin Therapeutics in a report on Friday, October 6th. Finally, Zacks Investment Research upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a report on Thursday, November 30th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $4.55.

Galectin Therapeutics (NASDAQ:GALT) traded down $0.18 during midday trading on Thursday, reaching $1.54. The company had a trading volume of 1,401,000 shares, compared to its average volume of 393,419. Galectin Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. equities analysts expect that Galectin Therapeutics will post -0.52 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in GALT. Northern Trust Corp grew its holdings in shares of Galectin Therapeutics by 4.4% during the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock worth $185,000 after buying an additional 3,176 shares in the last quarter. Virtu KCG Holdings LLC grew its holdings in shares of Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after buying an additional 21,008 shares in the last quarter. Advisor Group Inc. grew its holdings in shares of Galectin Therapeutics by 10.4% during the second quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock worth $1,191,000 after buying an additional 45,700 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after buying an additional 134,165 shares in the last quarter. Institutional investors own 11.07% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Galectin Therapeutics (GALT) Given New $3.00 Price Target at Roth Capital” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/07/galectin-therapeutics-galt-given-new-3-00-price-target-at-roth-capital.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.